Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.
Fauvre A, Machu M, Merienne A, Vie N, Bessede T, Robin M, Garambois V, Taffoni C, Laguette N, Gervois-Segain N, Jarry A, Labarriere N, Allory Y, Larbouret C, Gros L, Tosi D, Solit DB, Pourquier P, Houédé N, Gongora C. Fauvre A, et al. Among authors: gongora c. Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011. Clin Transl Med. 2024. PMID: 39269751 Free PMC article. No abstract available.
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Rabia E, et al. Among authors: gongora c. MAbs. 2021 Jan-Dec;13(1):1914883. doi: 10.1080/19420862.2021.1914883. MAbs. 2021. PMID: 33876707 Free PMC article.
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C. Ogier C, et al. Among authors: gongora c. Cancer Lett. 2018 Sep 28;432:227-236. doi: 10.1016/j.canlet.2018.06.023. Epub 2018 Jun 20. Cancer Lett. 2018. PMID: 29935372
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, Jarlier M, Denis V, Linares LK, Lam EW, Martineau P, Del Rio M, Gongora C. Marzi L, et al. Among authors: gongora c. Br J Cancer. 2016 Nov 8;115(10):1223-1233. doi: 10.1038/bjc.2016.313. Epub 2016 Sep 29. Br J Cancer. 2016. PMID: 27685445 Free PMC article.
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.
Combès E, Andrade AF, Tosi D, Michaud HA, Coquel F, Garambois V, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Moreaux J, Martineau P, Del Rio M, Beijersbergen RL, Vezzio-Vie N, Gongora C. Combès E, et al. Among authors: gongora c. Cancer Res. 2019 Jun 1;79(11):2933-2946. doi: 10.1158/0008-5472.CAN-18-2807. Epub 2019 Apr 15. Cancer Res. 2019. PMID: 30987998
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.
Cherradi S, Garambois V, Marines J, Andrade AF, Fauvre A, Morand O, Fargal M, Mancouri F, Ayrolles-Torro A, Vezzo-Vié N, Jarlier M, Loussaint G, Huvelle S, Joubert N, Mazard T, Gongora C, Pourquier P, Boissière-Michot F, Rio MD. Cherradi S, et al. Among authors: gongora c. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5. Cell Biosci. 2023. PMID: 37041570 Free PMC article.
112 results